Loading stock data…
Structure Therapeutics Inc. (GPCR)
$40.38-6.96 (-14.70%)
Market ClosedLast close Sep 8
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Structure Therapeutics Inc. in the Healthcare sector is trading at $40.38 with a market capitalization of $2.7B. Wall Street consensus targets $105.78 (15 analysts), implying a +162.0% move over the next 12 months. The stock is currently 57% below its 52-week high of $94.90, remaining 25.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +162.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 17) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$118.63M↓ | -$89.38M↓ | $13.74M↑ | -$73.79M↓ | -$70.45M |
| Net Income | -$106.16M↓ | -$75.97M↓ | $33.00M↑ | -$65.71M↓ | -$61.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.74B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.77%
Volume
Today's trading volume
3.40M
Recent News
Structure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron Trial
Structure Therapeutics (GPCR) said Tuesday that a single dose of its ACCG-2671 drug candidate reduce
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.
Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 7, Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) and set a price target of $101. The firm’s price target implies an additional 95% upside from current levels. In addition to Prakhar […]
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer embedded in its business and a share price that looks like a mistake.
H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money. On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. (NASDAQ:GPCR) from $100 to $70, which still leads to an adjusted upside potential of more than 61%. The firm upheld its Buy rating on the […]